Drug intelligence / Profile preview

AST-1138

Development stage: Unknown
Lead developer: Aston
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

AST-1138 is an investigational therapeutic vaccine and mRNA vaccine targeting KRAS, specifically developed as a KRAS modulator. Its mechanism of action involves modulation of the GTPase KRas protein (KRAS), which is a well-known oncogenic driver in various cancers. The drug is being developed by Aston SCI for the treatment of neoplasms associated with KRAS mutations, particularly KRAS mutation-related tumors. As of June 2025, its highest development status is at the Discovery stage[1].

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on AST-1138.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-1138.

Explore the full profile